Key Points
- Director Edward Md Kaye sold 12,567 Stoke Therapeutics shares at an average price of $32.03, generating $402,521.01. The sale covered tax withholding obligations tied to vested equity awards and reduced his ownership by 9.16%.
- Stoke Therapeutics reported quarterly revenue of $9.32 million, exceeding estimates, but its adjusted loss of $0.93 per share was wider than the expected $0.80 loss. The company posted a negative net margin of 753.60%.
- Analysts remain broadly positive, with nine Buy ratings, one Hold and one Sell, producing a “Moderate Buy” consensus and an average price target of $43 versus the stock’s approximately $32 price.
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) General Counsel Jonathan Allan sold 2,861 shares of the firm's stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total transaction of $91,637.83. Following the completion of the transaction, the general counsel directly owned 21,225 shares in the company, valued at $679,836.75. This trade represents a 11.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Jonathan Allan also recently made the following trade(s):
- On Tuesday, June 16th, Jonathan Allan sold 1,457 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.95, for a total value of $43,637.15.
Stoke Therapeutics Stock Performance
NASDAQ:STOK opened at $32.14 on Wednesday. Stoke Therapeutics, Inc. has a one year low of $18.00 and a one year high of $40.22. The stock has a market cap of $2.07 billion, a PE ratio of -9.62 and a beta of 1.20. The stock has a 50 day moving average price of $30.81 and a 200 day moving average price of $32.21.
Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.13). The company had revenue of $9.32 million for the quarter, compared to analysts' expectations of $4.89 million. Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%. As a group, analysts predict that Stoke Therapeutics, Inc. will post -3.5 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Stoke Therapeutics
A number of large investors have recently bought and sold shares of STOK. BlackRock Inc. purchased a new stake in shares of Stoke Therapeutics during the 2nd quarter valued at $192,307,000. RTW Investments LP lifted its stake in shares of Stoke Therapeutics by 8.3% in the 4th quarter. RTW Investments LP now owns 5,546,856 shares of the company's stock valued at $176,057,000 after purchasing an additional 423,331 shares in the last quarter. Redmile Group LLC grew its holdings in shares of Stoke Therapeutics by 3.2% during the 1st quarter. Redmile Group LLC now owns 4,164,120 shares of the company's stock worth $135,584,000 after purchasing an additional 130,050 shares during the period. Morgan Stanley grew its holdings in shares of Stoke Therapeutics by 0.3% during the 4th quarter. Morgan Stanley now owns 3,546,158 shares of the company's stock worth $112,555,000 after purchasing an additional 9,108 shares during the period. Finally, State Street Corp increased its position in Stoke Therapeutics by 75.2% during the 4th quarter. State Street Corp now owns 2,498,049 shares of the company's stock worth $79,288,000 after purchasing an additional 1,072,176 shares in the last quarter.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on STOK. Guggenheim restated a "buy" rating and issued a $60.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, August 4th. Canaccord Genuity Group lowered their price target on shares of Stoke Therapeutics from $60.00 to $58.00 and set a "buy" rating for the company in a report on Tuesday, August 4th. The Goldman Sachs Group assumed coverage on shares of Stoke Therapeutics in a report on Monday, July 13th. They set a "buy" rating and a $44.00 price objective on the stock. Chardan Capital reaffirmed a "buy" rating and issued a $35.00 target price on shares of Stoke Therapeutics in a report on Tuesday, August 4th. Finally, Weiss Ratings restated a "sell (d)" rating on shares of Stoke Therapeutics in a research report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Stoke Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $43.00.
View Our Latest Stock Report on Stoke Therapeutics
Stoke Therapeutics Company Profile
(
Get Free Report)
Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.
The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
